T here is considerable evidence from studies in both human and animal models that estrogen plays an important role in cardiovascular health. 1 Whereas approximately one third of the clinical advantages of estrogen can be attributed to changes in circulating lipid levels, [2] [3] [4] [5] there are also important direct effects on the vascular wall, including changes in endothelial cell gene expression and function. Long-term estrogen exposure upregulates the expression of endothelial cell genes, including cyclooxygenase (COX)-1 and endothelial NO synthase (eNOS), 6 -8 and it inhibits cytokinemediated endothelial cell adhesion molecule expression. 9 Estrogen also has rapid nongenomic effects on endothelial cells, which include NO activation and prostacyclin production within minutes of hormone exposure. 10 -13 It is most likely a combination of genomic and nongenomic processes that underlies the capacity of estrogen to have a beneficial impact on vascular health. 1 The actions of estrogen in most paradigms are mediated by estrogen receptors (ERs), which classically serve as transcription factors. There are two known ER subtypes, designated ER␣ and ER␤, and the expression of both isoforms has been observed in endothelial cells in multiple model systems. 14 The two ER isoforms share significant homology in their DNA binding and ligand binding domains (95% and 55%, respectively), but they vary greatly in their N terminal (A/B) domains, which contain the ligand-independent transcriptional activation function TAF-1. ER␣ and ER␤ also have opposite effects on the activation of estrogen responsive promoters containing an activator protein-1 site, with ER␣ activating and ER␤ attenuating transcription. 15, 16 As might be predicted from their known functions as steroid hormone receptors and transcription factors, ERs mediate estrogen-induced COX-1 and eNOS upregulation and estrogen-induced adhesion molecule downregulation in cultured endothelial cells. 6, 8, 9 In addition, there is evidence that ERs are critically involved in the nongenomic actions of estrogen in endothelial cells; this evidence includes a study indicating that ER␣ plays a key role in eNOS activation by the hormone. 17 Further studies have indicated that the latter processes involve a subpopulation of ER␣ associated with plasma membrane caveolae. 18 -20 Recent work in transgenic mice in which either ER␣ or ER␤ expression has been disrupted has also revealed that ER␣, and not ER␤, mediates the long-term effects of estrogen on basal endothelial NO production in intact vasculature. 21, 22 Thus, a significant amount of knowledge is accumulating regarding the diverse roles of ERs (in particular, ER␣) in the vascular endothelium. In contrast, the mechanisms that regulate ER␣ expression in the endothelium are poorly understood.
To better understand the processes by which ER␣ abundance is modified in the vascular endothelium, the present investigation was designed to determine the direct effect of estrogen on the expression of the receptor in cultured endothelial cells. We raised the hypothesis that estrogen upregulates ER␣ expression in endothelial cells. In addition to testing this hypothesis, experiments were performed to address the following questions: (1) What is the temporal nature of estrogen action on endothelial ER␣ expression? (2) Does estrogen have comparable effects on endothelial ER␣ and ER␤ expression? (3) Is the effect of estrogen on ER␣ expression transcriptionally based? (4) Is the effect of estrogen on endothelial ER␣ expression mediated through ER␣ and/or ER␤?
Materials and Methods

Cell Culture and Treatment
Primary endothelial cells were obtained from the intrapulmonary arteries of mixed-breed fetal sheep at 125 to 135 days of gestation, with term being 144Ϯ4 days, using methods that we have previously described. 23 These cells were chosen because they continue to faithfully express ER␣ and ER␤ in cell culture. 8, 13 Cells from four different primary cultures were studied at passages 4 to 6. Before study, nearly confluent cells were placed in phenol red-free serumfree medium to remove the effects of the estrogen-like activity of phenol red and estrogen derived from the serum. The procedures followed for the care and use of the sheep were approved by the Institutional Animal Care and Research Advisory Committee of the University of Texas Southwestern Medical Center.
To determine the dose response to estrogen, cells were treated with vehicle or 17␤-estradiol (E 2 , 10 Ϫ14 to 10 Ϫ6 mol/L) every 18 hours and harvested at 48 hours. To further evaluate the time course of the effect of E 2 , cells were treated once with vehicle or with 10 Ϫ8 mol/L E 2 and harvested at 6, 12, and 24 hours. In additional experiments, cells were treated with E 2 and harvested at 2, 4, and 6 hours. E 2 stock solutions were prepared in ethanol (1 mg/mL), and appropriate dilutions of ethanol served as vehicle controls. Studies with vehicle alone versus medium alone showed a transient decline in ER␣ expression that resolved by 12 hours. The effects of nonselective ER antagonism were assessed using ICI 182,780 (10 Ϫ5 mol/L), and the role of gene transcription was determined using actinomycin D (25 g/mL). 17 ICI 182,780 did not alter ER␣ protein abundance in the absence of estrogen. Nor did actinomycin D modify ER␣ expression in the absence of ligand, yielding abundance that was 120Ϯ25% (meanϮSEM, nϭ5) of control values.
Immunoblot Analyses
Immunoblot analyses were performed using methods modified from those previously reported. 24 Cells were harvested in ice-cold PBS containing 138 mmol/L NaCl, 2.67 mmol/L KCl, 1.47 mmol/L KH 2 PO 4 , and 8.10 mmol/L Na 2 HPO 4 ; they were pelleted and resuspended in 50 mmol/L Tris buffer (pH 7.4) containing 16 mmol/L CHAPS, 100 mmol/L NaCl, 0.5 mmol/L EDTA, 0.02 mmol/L EGTA, 0.4 mmol/L ␤-mercaptoethanol, 1.6 mmol/L dithiothreitol, and 2 g/mL each of soybean trypsin inhibitor, lima bean trypsin inhibitor, antipain, and leupeptin; and then they were ultrasonically disrupted (Branson Ultrasonics). The protein content of the preparations was determined by Bradford assay, 25 and SDS-PAGE was performed on equal protein samples (40 g each).
Coomassie blue staining was used to confirm equal protein loading. The proteins were electrophoretically transferred to polyvinylidene difluoride membranes (Millipore Corp) over 2 hours on ice, and the membranes were blocked for 1 hour at room temperature in buffer containing 137 mmol/L NaCl and 20 mmol/L Tris (pH 7.5) with 0.5% Tween 20 and 5% dried milk and incubated overnight at 4°C with monoclonal antibody to ER␣ (AER320, 2 g/mL, NeoMarkers, Inc) or polyclonal antibody to ER␤ (1 g/mL, Affinity BioReagents Inc). ER␣-and ER␤-positive controls consisted of lysates of COS-7 cells transfected with human ER␣ or murine ER␤ cDNA. The membranes were washed three times and incubated with secondary antibody for 1 hour. The membranes were again washed, and signal for ER␣ or ER␤ protein was visualized by chemiluminescence (ECL Western Blotting Analysis System, Amersham). Amido black staining was used to confirm equivalence of the protein loads on the membranes.
ER␣ Promoter Activity
The human ER␣ gene promoter P-1 (Ϫ900 to 212 relative to the major transcription start site) was kindly provided by Dr Myles Brown (Dana Faber Institute, Boston, Mass). 26 P-1 was cloned into the pGL2 luciferase reporter gene (ER␣Ϫ900/ϩ212-LUC) using standard techniques. Cell transfection was performed using methods modified from those previously reported. 8 Cells grown to 60% to 70% confluence in 6-well plates were washed once with OptiMEM medium (Life Technologies, Inc) and preincubated in OptiMEM medium for 20 minutes at 37°C. ER␣Ϫ900/ϩ212-LUC and a plasmid containing SV-40 -driven ␤-galactosidase (pSV-␤-Gal, Promega Corp) to normalize for transfection efficiency were mixed (1 g per well of each) with LipofectAMINE (10 L per well, Life Technologies, Inc) and incubated in a total volume of 200 L for 30 minutes at room temperature. The lipid-coated DNA and 800 L of Opti-MEM were added to each well of cells. After 3 hours, 2 mL medium was added. In selected wells, the cells were alternatively transfected with pGL2-Control Vector (Promega Corp) containing an SV-40 promoter and enhancer or with pGL2-Basic Vector lacking the SV-40 promoter and enhancer (Promega Corp), serving as positive and negative controls, respectively. Twenty-four hours after transfection, the cells were washed in phenol red-free serum-free medium and placed in phenol red-free medium containing 10% charcoal-stripped serum. The charcoal stripping removes estrogen metabolites and other steroid hormones. The cells were treated for 2 to 48 hours with control medium or medium containing 10 Ϫ8 mol/L E 2 , with repeat treatments every 18 hours. The cells were lysed, and the extracts were centrifuged at 12 000g to remove unbroken cells and debris. Luciferase activity was measured using a luminometer (Moonlight 2010, Analytical Luminescence Laboratory), 27 and ␤-galactosidase activity was determined spectrophotometrically (at 420 nm) by the generation of o-nitrophenol from the substrate o-nitrophenyl-␤-D-galactopyranoside. 28 The results were normalized as relative luciferase light units/␤-galactosidase activity.
The role of ER in the regulation of promoter activity was determined by treatment with the nonselective ER antagonist ICI 182,780 (10
Ϫ7 mol/L), which is a selective ER␤ antagonist and an ER␣ agonist in certain paradigms. 29 THC was the kind gift of John and Benita Katzenellenbogen (University of Illinois at Urbana-Champaign College of Medicine, Chicago, Ill). To determine the role of ER subtypes in an additional independent manner, studies were performed in endothelial cells cotransfected with either sham plasmid or human ER␣ or murine ER␤ cDNA.
Statistical Analysis
Comparisons between two groups were made by nonpaired Student t tests. Findings in Ն3 groups were assessed by ANOVA and Newman-Keuls post hoc testing. Results are expressed as meanϮSEM, and all stated differences achieved statistical significance at PՅ0.05.
Results
Effect of E 2 on ER␣ Expression
To first determine whether estrogen modifies ER␣ expression in endothelial cells, the effects of varying concentrations of E 2 were evaluated over 48 hours, with repeat treatments with E 2 every 18 hours (Figure 1 ). Such an approach was taken because E 2 -mediated changes in the expression of other genes in endothelial cells has required 48 hours of exposure to the hormone. 6, 8 In the representative immunoblot shown ( Figure  1A ), ER␣ abundance was increased after 48 hours of E 2 treatment at 10 Ϫ10 to 10 Ϫ8 mol/L. Cumulative findings from four independent experiments confirmed these results ( Figure  1B) , showing a 210% increase in ER␣ protein abundance after treatment with E 2 at 10 Ϫ10 to 10 Ϫ8 mol/L. The time course for the change in ER␣ protein expression after a single treatment with E 2 is presented in Figure 2 . The time-course experiments for 6 to 24 hours ( Figures 2C and 2D ) were performed first, and the observations obtained prompted additional experiments focused on time points up to 6 hours (Figures 2A and 2B ). In the representative immunoblot shown for the early time course (Figure 2A ), compared with vehicle, E 2 caused a decline in ER␣ protein abundance at 2 hours; there was no difference in control or treated samples at 4 hours; and the ER␣ protein level was markedly greater with 10 Ϫ8 mol/L E 2 compared with vehicle control at 6 hours. Densitometric analyses of four experiments confirmed these findings, revealing a 33% decline in ER␣ abundance at 2 hours, unaltered abundance at 4 hours, and a 2.9-fold increase in ER␣ expression at 6 hours ( Figure 2B ). In the representative immunoblot shown for the later time course (Figure 2C ), ER␣ protein levels were greater with E 2 treatment for 6 or 12 hours, but the increase was no longer evident at 24 hours. Cumulative results from four studies yielded 2.7-and 2.5-fold increases in receptor abundance at 6 and 12 hours of E 2 , respectively, and no change from control cells at 24 hours ( Figure 2D ).
Role of ER Activation in ER␣ Modulation by E 2
The importance of ER activation in changes in ER␣ expression induced by E 2 in endothelial cells was evaluated using ICI 182,780, which is a nonselective antagonist of ER␣ and ER␤. In the representative immunoblot shown ( Figure 3A) , 48 hours of treatment with E 2 caused an increase in ER␣ protein abundance, and the upregulation was prevented by ICI 182,780. Cumulative findings from four studies revealed a 3.6-fold increase in ER␣ protein with E 2 and complete reversal of this effect by ER antagonism ( Figure 3B ).
Effect of E 2 on ER␤ Expression
To determine whether the findings for E 2 modulation of ER␣ expression in endothelial cells are unique to that ER subtype, parallel studies of ER␤ expression were performed ( Figure  4) . In contrast to the upregulation in ER␣ noted after 48 hours of exposure to E 2 , there was a decline in ER␤ protein abundance ( Figure 4A ). The effect of E 2 on ER␤ expression was reversed by nonselective ER antagonism with ICI 182,780. Repeated studies demonstrated a 56% decline in ER␤ protein expression with long-term E 2 treatment ( Figure  4B ). In contrast, E 2 exposure for 2, 4, 6, or 12 hours did not alter ER␤ expression, with abundance observed to be 104Ϯ9%, 111Ϯ14%, 98Ϯ9%, and 99Ϯ22% of control values (meanϮSEM, nϭ4) for the same time points, respectively.
E 2 and ER␣ Gene Transcription in Endothelium
To determine the role of gene transcription in ER␣ modulation by E 2 , studies were performed with actinomycin D. In the representative experiment shown, E 2 treatment for 48 hours yielded an increase in ER␣ protein, and this was completely prevented by actinomycin D (Figure 5A ). Summary results for three separate studies confirmed these observations (Figure 5B) , indicating a 615% increase in ER␣ protein with E 2 that was negated by actinomycin D treatment.
To determine whether E 2 stimulates ER␣ gene transcription in endothelial cells, the activity of the human ER␣ promoter was assessed using the promoter-luciferase reporter construct ER␣Ϫ900/ϩ212-LUC. Basal ER␣ promoter activity was detectable in the endothelial cells, and E 2 (10 Ϫ8 mol/L) treatment for 48 hours increased promoter activity by 3-fold ( Figure 6A ). In addition, E 2 -stimulated promoter activity was fully prevented by ICI 182,780. Early time-course studies revealed activation of ER␣ gene transcription within 4 hours of E 2 exposure ( Figure 6B ).
To determine whether ER␣ or ER␤ are capable of activation of ER␣ gene transcription in endothelial cells, additional studies were performed in endothelial cells cotransfected with ER␣ or ER␤ cDNA ( Figure 7A ). Overexpression of ER␣ resulted in 10-fold greater promoter activation by E 2 compared with shamtransfected cells. Similarly, overexpression of ER␤ yielded 8-fold greater promoter activation by the hormone. The roles of endogenous ER␣ and ER␤ were assessed by comparing E 2 -induced ER␣ promoter activation in the presence of ICI 182,780, which is an antagonist for both receptor subtypes, versus THC, which is an ER␤ antagonist and an ER␣ agonist under certain conditions ( Figure 7B ). 29 Whereas ICI 182,780 caused 82% inhibition of E 2 -stimulated promoter activity, THC treatment resulted in 43% inhibition.
Discussion
Estrogen has important effects on both nongenomic and genomic processes in the vascular endothelium, and many of these effects occur through ER␣ activation. 30 However, little is known about the processes whereby endothelial ER␣ expression is mediated. In the present study, we determined the direct impact of the hormone on the expression of the receptor in cultured endothelial cells. We demonstrate that long-term exposure to physiological levels of E 2 causes ER␣ protein upregulation, indicating that the ligand has potent effects on the expression of its own receptor in endothelium.
We observed that the initial (2-hour) exposure to E 2 causes a decline in endothelial ER␣ protein abundance. This finding parallels the fall in ER␣ levels initially described in the uterus after estrogen administration to rats 31, 32 and in cultured uterine cells and breast cancer cell lines after estrogen exposure. 31, 33 More recent work in transfected cells has demonstrated that ER␣ is degraded by the ubiquitin-proteasome pathway in a hormonedependent manner and that such degradation is actually required for ER␣ to serve as a transcription factor. 34 After the initial decline in ER␣ protein abundance in endothelial cells, we observed an upregulation in the protein by 6 hours of hormone exposure. Compared with other paradigms, the recovery of ER␣ in endothelial cells is quite rapid, and it leads to receptor levels that are considerably greater than baseline. 31, 32 The studies performed at 48 hours after retreatment of the cells indicate that persistently elevated levels of the ligand will maintain the enhanced endothelial ER␣ expression. Collectively, the timecourse experiments indicate that the regulation of ER␣ expression in endothelial cells is a dynamic process that is biphasic if exposure to fresh ligand is persistent.
The role of ERs in endothelial ER␣ regulation was then determined using the ER-subtype nonselective antagonist ICI 182,780. Whereas long-term exposure to E 2 caused ER␣ upregulation, concomitant treatment with ICI 182,780 completely prevented the change in receptor abundance. This is the first direct evidence in any cell type of a role for the receptor in the regulation of its own expression at endogenous constitutive levels. As such, there is potential amplification of ER␣ action in endothelial cells with prolonged ligand activation.
Parallel studies of ER␤ expression were performed to determine whether the observations for endothelial ER␣ are unique to that receptor subtype. In contrast to the findings for ER␣, initial E 2 treatment did not modify ER␤ abundance, whereas there was marked downregulation of ER␤ on long-term exposure to the hormone. The latter process was also ER dependent. This is the first evidence of contrasting ER isoform regulation by the hormone. On the basis of these observations, it is apparent that the net effect of E 2 on endothelial cell signaling and/or gene expression represents the combination of potential overlapping and contrasting ER␣ and ER␤ actions in that cell type and also the opposing dynamics of ER-subtype expression. These considerations are important to the interpretation of findings in model systems using gain-of-function or loss-of-function strategies to delineate the roles of specific ER subtypes in the vascular wall.
The basis for E 2 -induced changes in ER␣ protein levels in the endothelium was then investigated using actinomycin D to inhibit gene transcription. Whereas the agent did not alter ER␣ abundance in the absence of hormone as ligand, actinomycin D completely prevented E 2 -related increases in the abundance of the receptor. Consistent with this observation, the activity of the human ER␣ promoter transfected in endothelial cells was increased by E 2 in an ER-dependent manner. Prior studies of the promoter in MCF7 or HeLa cells have shown that estrogen inducibility is mediated by three half-estrogen response elements, 26 and similar processes are likely to be active in endothelial cells. Importantly, it was possible to demonstrate robust activation of the ER␣ promoter within 4 hours of E 2 treatment, thus preceding the upregulation in protein expression observed at 6 hours and beyond. The activation of ER␣ gene transcription and the resultant upregulation in the protein in endothelial cells is extremely rapid compared with those in other endothelial cell genes that are regulated by the hormone, such as COX-1 and eNOS, whose expressions are not altered before 48 hours of hormone exposure. 6, 8 Additional experiments were performed to determine the receptor subtype responsible for ER␣ gene activation in endothelial cells. In cells cotransfected with the ER␣ promoterreporter construct and cDNAs for either ER␣ or ER␤, the overexpression of either receptor subtype yielded greater promoter activation by E 2 , indicating that both ER␣ and ER␤ are capable of mediating ER␣ gene expression. These findings were confirmed in studies using the ER␤-selective antagonist THC, which attenuated approximately half of E 2 -induced ERdependent promoter activation. Thus, the regulation of ER␣ expression in endothelial cells entails both homologous and heterologous sensitization.
The current observations add new insights to our prior understanding of the modulation of endothelial ER by estrogen. Previous studies that were limited to determinations of ER␣ mRNA levels in human umbilical vein endothelial cells demonstrated an increase in the mRNA after 48 hours of hormone exposure, 9 and this is consistent with the present findings. It has been shown with the use of radioligand binding assays that rat liver sinusoidal endothelial cell ER abundance declines after ovariectomy and increases after ethinyl estradiol treatment. 35 However, studies in whole mouse aortas have revealed greater E 2 binding sites in males versus females, and no changes were detected after long-term estrogen treatment. 21, 36 In addition, ER␣ and ER␤ expression in rat uterine endothelium evidently does not vary during the estrous cycle, but these observations were exclusively dependent on immunohistochemical approaches. 37 In contrast to these prior studies, the present work directly quantifies both ER␣ and ER␤ protein levels in endothelial cells. Although the current in vitro model system is potentially limited by the use of a single endothelial cell type removed from physiological conditions, such an approach has made it possible to determine the direct effects of E 2 on endothelial ER expression and to delineate the basic mechanisms underlying the changes in ER␣ abundance. Further studies are now warranted using receptor-subtype-specific quantitative measures in intact animal models to determine how estrogen alters endothelial ER␣ and ER␤ expression in multiple vascular beds.
The physiological and pathophysiological implications of the present findings are many. Consistent with the apparent complexities in the temporal nature of ER regulation in the vascular endothelium, prior studies of estrogen-induced vascular responses have yielded a variety of time courses of hormone effect. As suggested previously by Parker et al, 38 there are at least three patterns of response. There are rapid vasodilator responses within 5 minutes, such as those observed in isolated coronary artery rings from human adult males. 39 In contrast, vasodilation in the uterine arteries of nonpregnant ewes is delayed for 40 minutes and peaks at 100 minutes before falling back to baseline over several hours. 40 Other models display delayed vasodilator responses that occur after days of hormone exposure, such as the effect of E 2 on the pulmonary circulation of the ovine fetus. 38 Whereas the temporal characteristics of the vascular responses to estrogen may be due to multiple mechanisms, 30 it is postulated that initial endothelial ER degradation and ultimate ER␣ upregulation or ER␤ downregulation may be involved. In addition, conditions of estrogen deficiency, such as surgical or natural menopause, may be characterized by perturbed endothelial ER expression, thereby potentially contributing to the increase in vascular disease associated with those states. 1, 3, 14, 30 Future directed studies of the regulation of ER␣ and ER␤ expression in the endothelium will increase our basic understanding of the mechanisms by which estrogen has an impact on vascular health.
